trending Market Intelligence /marketintelligence/en/news-insights/trending/rgujb0fVGKy20sMe6ebqQQ2 content esgSubNav
In This List

BioXcel Therapeutics prices $19M common stock offering

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


BioXcel Therapeutics prices $19M common stock offering

BioXcel Therapeutics Inc. priced an offering of 2,303,030 common shares at $8.25 apiece to raise about $19 million gross proceeds.

The New Haven, Conn.-based biopharmaceutical company granted the underwriters an option to buy up to 345,454 additional common shares in the offering.

The transaction is expected to be completed Sept. 30, subject to customary closing conditions.

BMO Capital Markets Corp. is acting as book-running manager for the offering, with ThinkEquity as co-manager.